FRTX | tickerfilter.com

Fundamental analysis

Profitability 0%

Dept financing 0%

Liquidity 0%

Performance 10%

Performance

5 Days

0 0%

1 Month

0 0%

3 Months

0 0%

6 Months

-20.65%

1 Year

-9.88%

2 Year

-45.11%

Key data

Stock price

$0.83

P/E Ratio

-0.84

DAY RANGE

N/A - N/A

EPS

-$1.06

52 WEEK RANGE

$0.73 - $1.01

52 WEEK CHANGE

-$16.96

MARKET CAP

4.779 M

YIELD

N/A

SHARES OUTSTANDING

5.973 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

0.00

PUBLIC FLOAT

AVERAGE 10 VOLUME

N/A

AVERAGE 30 VOLUME

N/A

Company detail

CEO: Robert B. Brown
Region: US
Website: frtx.com
Employees: 20
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Brickell Biotech, Inc. engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofironium bromide, which has completed Phase III clinical trials for the. treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor, and BBI10, a covalent stimulator of interferon genes inhibitor.

FRTX - Fresh Tracks Therapeutics, Inc.